Literature DB >> 20144188

The TOPGAME-study: effectiveness of extracorporeal shockwave therapy in jumping athletes with patellar tendinopathy. Design of a randomised controlled trial.

Johannes Zwerver1, Evert Verhagen, Fred Hartgens, Inge van den Akker-Scheek, Ron L Diercks.   

Abstract

BACKGROUND: Patellar tendinopathy is a major problem for many athletes, especially those involved in jumping activities. Despite its frequency and negative impact on athletic careers, no evidence-based guidelines for management of this overuse injury exist. Since functional outcomes of conservative and surgical treatments remain suboptimal, new diagnostic and therapeutic strategies have to be developed and evaluated. Extracorporeal shockwave therapy (ESWT) appears to be a promising treatment in patients with chronic patellar tendinopathy. ESWT is most often applied after the known conservative treatments have failed. However, its effectiveness as primary therapy has not been studied in athletes who keep playing sports despite having patellar tendon pain. The aim of this study is to determine the effectiveness of ESWT in athletes with patellar tendinopathy who are still in training and competition. METHODS/
DESIGN: The TOPGAME-study (Tendinopathy of Patella Groningen Amsterdam Maastricht ESWT) is a multicentre two-armed randomised controlled trial with blinded participants and outcome assessors, in which the effectiveness of patient-guided focussed ESWT treatment (compared to placebo ESWT) on pain reduction and recovery of function in athletes with patellar tendinopathy will be investigated. Participants are volleyball, handball and basketball players with symptoms of patellar tendinopathy for a minimum of 3 to a maximum duration of 12 months who are still able to train and compete. The intervention group receives three patient-guided focussed medium-energy density ESWT treatments without local anaesthesia at a weekly interval in the first half of the competition. The control group receives placebo treatment. The follow-up measurements take place 1, 12 and 22 weeks after the final ESWT or placebo treatment, when athletes are still in competition. Primary outcome measure is the VISA-P (Victorian Institute of Sport Assessment - patella) score. Data with regard to pain during function tests (jump tests and single-leg decline squat) and ultrasound characteristics are also collected. During the follow-up period participants also register pain, symptoms, sports participation, side effects of treatment and additional medical consumption in an internet-based diary. DISCUSSION: The TOPGAME-study is the first RCT to study the effectiveness of patient-guided ESWT in athletes with patellar tendinopathy who are still in training and competition. TRIAL REGISTRATION: Trial registration number NTR1408.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20144188      PMCID: PMC2831826          DOI: 10.1186/1471-2474-11-28

Source DB:  PubMed          Journal:  BMC Musculoskelet Disord        ISSN: 1471-2474            Impact factor:   2.362


  14 in total

Review 1.  What is the most appropriate treatment for patellar tendinopathy?

Authors:  J L Cook; K M Khan
Journal:  Br J Sports Med       Date:  2001-10       Impact factor: 13.800

2.  Long-term prognosis for jumper's knee in male athletes. A prospective follow-up study.

Authors:  Jyrki A Kettunen; Martti Kvist; Erkki Alanen; Urho M Kujala
Journal:  Am J Sports Med       Date:  2002 Sep-Oct       Impact factor: 6.202

3.  The VISA score: an index of severity of symptoms in patients with jumper's knee (patellar tendinosis). Victorian Institute of Sport Tendon Study Group.

Authors:  P J Visentini; K M Khan; J L Cook; Z S Kiss; P R Harcourt; J D Wark
Journal:  J Sci Med Sport       Date:  1998-01       Impact factor: 4.319

4.  Prevalence of jumper's knee among elite athletes from different sports: a cross-sectional study.

Authors:  Oystein B Lian; Lars Engebretsen; Roald Bahr
Journal:  Am J Sports Med       Date:  2005-02-08       Impact factor: 6.202

5.  Jumper's knee.

Authors:  M E Blazina; R K Kerlan; F W Jobe; V S Carter; G J Carlson
Journal:  Orthop Clin North Am       Date:  1973-07       Impact factor: 2.472

Review 6.  Patellar tendinopathy in athletes: current diagnostic and therapeutic recommendations.

Authors:  Koen H E Peers; Roeland J J Lysens
Journal:  Sports Med       Date:  2005       Impact factor: 11.136

7.  Etiology and pathophysiology of chronic tendon disorders in sports.

Authors:  P Kannus
Journal:  Scand J Med Sci Sports       Date:  1997-04       Impact factor: 4.221

8.  Studies of surgical outcome after patellar tendinopathy: clinical significance of methodological deficiencies and guidelines for future studies. Victorian Institute of Sport Tendon Study Group.

Authors:  B D Coleman; K M Khan; N Maffulli; J L Cook; J D Wark
Journal:  Scand J Med Sci Sports       Date:  2000-02       Impact factor: 4.221

9.  Repetitive low-energy shock wave application without local anesthesia is more efficient than repetitive low-energy shock wave application with local anesthesia in the treatment of chronic plantar fasciitis.

Authors:  Jan D Rompe; Andrea Meurer; Bernhard Nafe; Alexander Hofmann; Ludger Gerdesmeyer
Journal:  J Orthop Res       Date:  2005-07       Impact factor: 3.494

10.  Validity and reliability of the Dutch translation of the VISA-P questionnaire for patellar tendinopathy.

Authors:  Johannes Zwerver; Tamara Kramer; Inge van den Akker-Scheek
Journal:  BMC Musculoskelet Disord       Date:  2009-08-11       Impact factor: 2.362

View more
  3 in total

1.  Prognostic factors of extracorporeal shock wave therapy for tendinopathies.

Authors:  A Notarnicola; G Maccagnano; S Tafuri; A Fiore; C Margiotta; V Pesce; B Moretti
Journal:  Musculoskelet Surg       Date:  2015-05-16

Review 2.  Clinical applications of platelet-rich plasma in patellar tendinopathy.

Authors:  D U Jeong; C-R Lee; J H Lee; J Pak; L-W Kang; B C Jeong; S H Lee
Journal:  Biomed Res Int       Date:  2014-07-21       Impact factor: 3.411

3.  Comparative study of treatment interventions for patellar tendinopathy: a protocol for a randomised controlled trial.

Authors:  Maria Pilar López-Royo; Eva Maria Gómez-Trullén; Maria Ortiz-Lucas; Rita Maria Galán-Díaz; Ana Vanessa Bataller-Cervero; Zaid Al-Boloushi; Yasmina Hamam-Alcober; Pablo Herrero
Journal:  BMJ Open       Date:  2020-02-16       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.